Houston innovator breaks down industry silos with new bp, NASA partnership

houston innovators podcast episode 252

Ken Nguyen, principal technical program manager at bp, joins the Houston Innovators Podcast to discuss the company's new partnership with NASA. Photo courtesy of bp

The recently announced partnership between bp and NASA is a match made in Houston. The energy giant, which as its United States headquarters in Houston, entered into a Space Act Agreement with NASA to combine resources and efforts with innovation in mind.

"Houston has always been known as the Space City, and we're also known as the Energy Capital of the World, but there hasn't always been collaboration," Ken Nguyen, principal technical program manager at bp, says on the Houston Innovators Podcast. "The challenges that NASA is facing is very similar to the challenges that the oil industry faces — we operate in very harsh environments, safety is the most critical aspect of our operation, and now the economic business model for NASA has changed."

Nguyen explains that while both bp and NASA are navigating similar challenges and changes within their industry, they are going about it in different ways. That's where the opportunity to collaborate comes in.

The partnership, which is still new and not fully fleshed out, will look at collaborative innovation into a few focus areas to start out with, including hydrogen storage and development, AI and general intelligence, robotics, and remote operations

"Houston continues to excel — in energy production and in space exploration — but by coming together," Nguyen says, "and for us to be able to tap into (NASA's) knowledge is tremendous. And we, within oil and gas, have a unique set of skills to blend into that with the hopes being that the city becomes this incubator for technology. The potential is there."

Nguyen oversees the implementation of new technologies at bp, and that includes software and hardtech, from cybersecurity to the digitization of the industry, which is an integral part of bp's energy transition plan, Nguyen says on the show.

"For bp, we do feel like as we transition as an international oil and gas company into an integrated energy company and we lean into the energy transition, the adoption of new technology is a critical part of making that viable for the planet and for the company," he says.

According to Nguyen, bp has invested its resources into exploring energy transition technologies like electric vehicle charging — including opening a fast-charging station at its Houston office — and renewable energy, including a solar farm about 10 miles northeast of Corpus Christi.

Another technology bp is keen on is digital twin technology, which can be crucial for enhancing safety for bp personnel and reducing emissions.

Nguyen says digital twin technology "allows us to be able to design and mirror scenarios with real-time variables, such as weather, off-take demands, and volatility."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."